Kidney transplant process sees shifts, but disparities persist

Written by The Life Science Feed Editorial Team · Published 4 August 2026 · Edited by Mara Voss

> Kidney transplantation remains the optimal treatment for many patients with end-stage renal disease, offering superior quality of life and survival compared to dialysis. But the process is complex, involving intricate logistical, medical, and ethical considerations that vary across regions and over time. Understanding these trends is essential for optimising outcomes and addressing unmet needs.

KEY TAKEAWAYS

- The Pivot: The E-STAR report details a continued shift in donor types and recipient profiles across Europe.
- The Data: The report outlines general trends in deceased and living donation, without specific numeric results.
- The Action: Clinicians should be aware of regional variations and systemic factors influencing access to transplantation.

The European Survey on Organ Donation and Transplantation (E-STAR) report provides an overview of kidney transplant activity across participating European countries. This annual compilation tracks general trends in donor characteristics, recipient demographics, and procedural aspects, offering a broad perspective on the evolving landscape of renal replacement therapy. It does not present specific trial data or efficacy numbers, but rather a descriptive analysis of practice patterns.

The report generally covers data from various national registries, consolidating information on deceased donor transplants, living donor transplants, and the characteristics of both donors and recipients. It aims to identify broad patterns and areas where practice might be diverging or converging across the continent. This is not a clinical trial, but a surveillance effort, providing a snapshot of real-world activity.

Evolving Donor and Recipient Profiles

The E-STAR report consistently shows an ongoing evolution in the types of donors contributing to the kidney transplant pool. There is a general trend towards an increasing utilisation of expanded criteria donors (ECD) and donation after circulatory death (DCD) organs. This reflects efforts to broaden the donor pool in the face of persistent organ shortages, though it also introduces complexities regarding organ quality and recipient matching. The report highlights that these organs, while necessary, often come with a higher risk profile for the recipient.

Recipient demographics are also shifting. Patients receiving kidney transplants are generally older and present with more comorbidities than in previous decades. This reflects improvements in pre-transplant medical management and a willingness to offer transplantation to a wider range of patients, including those who might have been considered too

high-risk previously. But this also places a greater burden on post-transplant care, requiring more intensive management of immunosuppression and comorbid conditions. Clinicians managing these patients often rely on comprehensive resources like the Oxford Handbook of Nephrology and Hypertension for practical guidance.

Persistent Disparities in Access

Despite the overall increase in transplant activity and the expansion of donor criteria, the E-STAR report consistently underscores persistent disparities in access to kidney transplantation across Europe. These inequities manifest in various forms, including differences in waiting list times, access to living donation programmes, and the utilisation of specific donor types between countries and even within regions of the same country. Such variations are often influenced by national healthcare policies, cultural attitudes towards organ donation, and the infrastructure available for organ retrieval and transplantation.

The report does not offer specific solutions, but it implicitly calls attention to the need for harmonisation of practices and policies to ensure more equitable access. For instance, some countries show significantly higher rates of living donation, which can dramatically reduce waiting times for recipients. Other regions rely almost exclusively on deceased donation, leading to longer waits and potentially poorer outcomes for patients on dialysis. These systemic differences are not easily overcome, but understanding them is the first step toward addressing them.

The Catch: Data Limitations

The E-STAR report, while valuable for its broad overview, relies on aggregated data from diverse national registries. This means that granular detail on specific outcomes, such as graft survival rates stratified by donor type or recipient comorbidity, is often not available. The report provides general trends, but it cannot offer the precision of a prospective clinical trial. It also does not account for the nuances of individual patient management or the impact of specific immunosuppressive regimens, which are critical determinants of long-term success.

The voluntary nature of data submission from participating countries also means that the completeness and consistency of the data can vary. This can make direct comparisons between countries challenging and limits the ability to draw definitive conclusions about best practices. Still, the report serves as an important benchmark for tracking the overall progress and challenges within European kidney transplantation, providing a high-level view that informs policy discussions and resource allocation.

> **CLINICAL IMPLICATIONS**
>
> The E-STAR report, while lacking the hard numbers of a clinical trial, provides a necessary reality check on the state of kidney transplantation in Europe. Clinicians should recognise that the 'ideal' transplant scenario is increasingly rare. We are transplanting older, sicker patients with more complex organs, which means post-transplant care is more demanding than ever. The days of simply prescribing a standard immunosuppressive regimen and sending patients on their way are long gone.
>
> The persistent disparities in access are particularly concerning. It is not enough to simply have organs available; the system must ensure equitable distribution. GPs and specialists need to be aware of the specific challenges and opportunities within their own national and regional systems. Advocating for patients on waiting lists, especially those in underserved areas, becomes a critical part of our role.
>
> For the industry, the report highlights the ongoing need for innovation in organ preservation,

> immunosuppression, and post-transplant monitoring. As the recipient pool becomes more complex, the demand for therapies that can mitigate rejection, manage comorbidities, and improve long-term graft survival will only grow. The market for solutions that address the challenges of expanded criteria donors and older recipients remains wide open.
>
> Ultimately, the report reinforces that kidney transplantation is not just a surgical procedure, but a lifelong journey for patients. The increasing complexity means that multidisciplinary care, robust patient education, and continuous monitoring are paramount. We must ensure our systems are equipped to support these patients for the long haul, not just through the initial surgery.

EDITORIAL & AI STANDARDS

AI tools are used to structure and summarise evidence from peer-reviewed primary sources. Articles that carry a signed Editor's take have been read in full by William Lopes. The others are not individually read by an editor, so check the cited source before relying on a figure.

REFERENCES

1. 1. Sexton DJ, Bagnasco S, Kant S. Transplant Nephrology. Adv Kidney Dis Health. 2024;31(6):566-573. doi:10.1053/j.akdh.2024.08.004
2. 2. Sykes M, Sachs DH. Progress in xenotransplantation: overcoming immune barriers. Nat Rev Nephrol. 2022;18(12):745-761. doi:10.1038/s41581-022-00624-6
3. 3. Levin A, Ahmed SB, Carrero JJ, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int. 2024;105(4):684-701. doi:10.1016/j.kint.2023.10.016
4. 4. Rosner MH, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: The intersections between the kidney and cancer. CA Cancer J Clin. 2021;71(1):47-77. doi:10.3322/caac.21636
5. 5. Herrmann SM, Abudayyeh A, Gupta S, et al. Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology. Kidney Int. 2025;107(1):21-32. doi:10.1016/j.kint.2024.09.017
6. 6. Roufosse C, Simmonds N, Clahsen-van Groningen M, et al. A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology. Transplantation. 2018;102(11):1795-1814. doi:10.1097/TP.0000000000002366

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com